Development of EMA401 as an orally-administered, highly-selective angiotensin II type 2 receptor antagonist for the treatment of neuropathic pain

Journal of the Peripheral Nervous System

Volumn 19, Issue S2, 2014, Pages S13-S14

  McCarthy, T ^a  

^a Spinifex Pharmaceuticals   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; EMA 401; GABAPENTIN; OPIATE; PLACEBO; PREGABALIN; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; BENZHYDRYL DERIVATIVE; EMA400; ISOQUINOLINE DERIVATIVE;

CLINICAL EFFECTIVENESS; CONFERENCE PAPER; DRUG EFFICACY; HOSPITALIZATION; HUMAN; NEUROPATHIC PAIN; PAIN INTENSITY; POSTHERPETIC NEURALGIA; RATING SCALE; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT; DOUBLE BLIND PROCEDURE; FEMALE; MALE; MULTICENTER STUDY (TOPIC); NEURALGIA, POSTHERPETIC; ORAL DRUG ADMINISTRATION; PAIN MEASUREMENT; PHASE 2 CLINICAL TRIAL (TOPIC);

ADMINISTRATION, ORAL; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; BENZHYDRYL COMPOUNDS; CLINICAL TRIALS, PHASE II AS TOPIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOQUINOLINES; MALE; MULTICENTER STUDIES AS TOPIC; NEURALGIA, POSTHERPETIC; PAIN MEASUREMENT;

EID: 84907900413     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns.12080_4     Document Type: Conference Paper

References (3)

1. Anand U, Facer P, Yiangou Y, Sinisi M, Fox M, McCarthy T, Bountra C, Korchev YE, Anand P (2013). Angiotensin II type 2 receptor (AT2R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons. Eur J Pain 17:1012-1026.
2. Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS (2005). Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2:e164.
3. Rice AS, Dworkin RH, McCarthy TD, Anand P, Bountra C, McCloud PI, Hill J, Cutter G, Kitson G, Desem N, Raff M; EMA401-003 study group (2014). EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 383:1637-1647.